secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2024-07-18T23:59:59+00:00
Accession:  0001326110-24-000093
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio settles IP lawsuit with HCW, acquires TGFb trap assets and licenses
-------------------------------------------------------------------------------

- Settlement resolves arbitration and federal lawsuit with HCW Biologics; no monetary consideration from ImmunityBio.
- ImmunityBio receives ownership of IP and drug candidates HCW9218, HCW9219, HCW9209 for TGFb-related fusion proteins.
- HCW9218 is a bifunctional fusion protein (TGFb trap + IL-15) studied in Phase 1/1b trials for ovarian and pancreatic cancer.
- ImmunityBio also gets exclusive license to use TF Platform for oncology targets PDL-1, IL-7, IL-12, IL-18, IL-21, plus one more.
- Parties exchange mutual releases; ImmunityBio to dismiss arbitration after compliance with settlement terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611024000093/0001326110-24-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611024000093/ibrx-20240713.htm
  HTML page:      https://secwatch.observer/filing/0001326110-24-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer